Physician profile
Robert Wolfgang
NPI 1871587550
$6,771.68
in general payments reported to CMS, 2019-2025
28 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $283 · 2021: $835 · 2022: $892 · 2023: $1,482 · 2024: $1,587 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,072 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.38 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,289.78 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $685.63 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $431.01 | 2020-2025 | Entyvio, Eohilia |
| Pfizer INC. | $416.83 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.07 | 2019-2024 | Trulance, Xifaxan |
| Medtronic, INC. | $278.76 | 2021 | |
| Celgene Corporation | $187.42 | 2022-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $121.60 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $114.31 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $100.64 | 2019-2023 | Exalt Model D |
| Ardelyx, INC. | $99.00 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $76.67 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $65.81 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $58.80 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $55.00 | 2019-2025 | Sucraid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $51.97 | 2019 | |
| Merck Sharp & Dohme LLC | $50.98 | 2019-2020 | |
| Allergan, INC. | $47.87 | 2019 | |
| Lilly USA, LLC | $47.30 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $44.98 | 2022-2023 | |
| Genzyme Corporation | $43.28 | 2023 | |
| Ferring Pharmaceuticals INC. | $36.12 | 2023 | Rebyota |
| Organon LLC | $33.95 | 2024 | |
| Erbe USA INC | $20.36 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $20.32 | 2024 | |
| Braintree Laboratories, INC. | $19.33 | 2021 | |
| Capsovision, INC. | $17.67 | 2025 | Capsocam Plus |
| Daiichi Sankyo INC. | $17.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wolfgang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.